Leflore Technologies

Leflore Technologies is a preclinical-stage biotechnology company focused on developing targeted therapeutics using its proprietary Elastin-like Polypeptide (ELP) drug delivery platform. Spun out of the University of Mississippi Medical Center, the company's technology utilizes bioengineered protein polymers derived from human tropoelastin to stabilize therapeutic peptides and proteins, extend their plasma half-life, and enable organ-specific targeting while preventing off-target exposure (such as placental transfer). Leflore's lead program, ELP-VEGF (or KTP-ELP-VEGF), is a novel biologic therapy designed to promote renal therapeutic angiogenesis and restore microvascular density in renovascular disease and chronic kidney disease. Additionally, the company is developing SynB1-ELP-p50i, an NF-κB inhibitor for preeclampsia and traumatic brain injury, and ELP-P10 for cytomegalovirus infections.